

Kollicoat® MAE 100-55

A complete match – just better.



We create chemistry

Kollicoat® MAE 100-55 combines two things hard to bring together – it can directly exchange the comparable pH 5.5 enteric release coating polymer in your commercial formulations, and still bring significant handling improvement to your operators because it does not dust at all.

Kollicoat® MAE 100-55 is the latest addition to our comprehensive portfolio of functional excipients in our Instant & Modified Release Platform. It extends our offer of pH >5.5 enteric release products based on methacrylic acid-ethylacrylate copolymer, providing you even more flexibility.


Kollicoat® MAE 100-55

- Direct substitution in commercial formulations
- Easier handling due to dust-free material
- Compliant with respective monographs

Kollicoat® MAE 100-55 (non-neutralized powder)	Kollicoat® MAE 100 P (pre-neutralized powder)	Kollicoat® MAE 30 DP (dispersion 30%)
<ul style="list-style-type: none">■ Allows direct substitution in commercial formulations■ Aqueous & organic coating	<ul style="list-style-type: none">■ No neutralization required■ Suitable for extreme weather (powder)■ Aqueous coating	<ul style="list-style-type: none">■ Most efficient and cost-effective (not spray-dried)■ Aqueous coating■ Not suitable for freezing climate
Ph.Eur. Monograph Type A	Ph.Eur. Monograph Type B	Ph.Eur. Monograph Dispersion

No more dusting thanks to unique powder particle shape

The dry powder particles of Kollicoat® MAE 100-55 are larger and thus significantly less dusty than comparable 100-55 coating grades – much easier to work with for your operators.



Kollicoat® MAE 100-55



Comparable non-neutralized dry powder

Pharma Solutions.

Focusing on your needs with platform solutions.

Instant & Modified Release | Solubilization | Skin Delivery | Softgels | Biologic Solutions

Kollicoat® MAE 100-55


A complete match – just better.



We create chemistry

Equivalent drug release

Despite its advantages in handling, Kollicoat® MAE 100-55 provides equivalent drug release as existing comparable coating grades in the market. And this means you can directly introduce it into your commercialized formulations.



Coated Bupropion HCl tablets (150mg);
N = 3; 50 rpm;
Buffer change after 2 h;
880ml HCl + 20 ml Tri-K phosphate

Quality and regulatory status:

Kollicoat® MAE 100-55 is produced in Germany under GMP conditions. It complies to respective Ph.Eur., USP-NF and JPE monographs:

- Ph.Eur.** Methacrylic Acid – Ethyl Acrylate Copolymer (1:1) Type A
USP/NF Methacrylic Acid and Ethyl Acrylate Copolymer NF (revision Dec 1st, 2015)
JPE Dried Methacrylic Acid Copolymer LD

Talk to our experts:

- | | | |
|---------------|-----------------|--|
| Asia Pacific | Satish Moorkath | satish.moorkath@basf.com |
| North America | Suzanna Brown | suzanna.brown@basf.com |
| Europe | Peter Hoffmann | peter.wolfgang.hoffmann@basf.com |
| South America | Marien Oliveira | marien.oliveira@basf.com |

BASF's rich portfolio of instant and modified release solutions offers an unparalleled range of functionality. Our high quality, industry-leading products enable you to formulate pharmaceuticals with the exact release properties you desire. This ensures the right results every time – giving you that all-important competitive edge. BASF can help with Instant & Modified Release, Solubilization, Softgels, Skin Delivery and Biologics related formulation challenges.